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Abstract
In recent years the future position of clinical endocrinology has been extensively discussed by Western
European endocrine societies. Clinical endocrinology seems to suffer from being too intellectual,
generating too little income, and lacking too few spectacular interventions. In this manuscript we
describe ‘the endocrine patient’ of the past, the present, and the future. Complete therapeutic break-
throughs resulting in ‘cure’ are compared with ‘halfway technologies’ which help in creating the (life-
long) chronic endocrine patient. The potential use of molecular diagnostics in optimalizing hormone
replacement therapy is discussed. Clinical endocrinology is at risk of developing into a subspecialty
where life-style drugs created for new diseases or conditions are offered, but also actively pursued
by otherwise healthy individuals (e.g. in normal short stature, regulation of appetite, body compo-
sition, sexuality, reproduction and aging). The potential opportunities and risks for clinical
endocrinology in creating ‘the endocrine patient’ of the future are discussed.
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Introduction
There is a continuous evolution within and between
the disciplines, both scientifically and in terms of clini-
cal practice. These developments also affect clinical
endocrinology, a subspecialty in internal medicine
and pediatrics which became established in the 1950s.
In a recent series of articles in which the current pos-
ition of clinical endocrinology in a number of European
countries was discussed, several potential threats con-
cerning the future were raised (1–7). Endocrinology
is perceived by some to have an ‘identity’ problem,
with regard to its importance as a subspecialty in
internal medicine. More and more general prac-
titioners, cardiologists, nephrologists, urologists, and
gynecologists actively participate in the care of endo-
crine patients. As endocrinologists in general do not
carry out sophisticated and expensive (i.e. ‘money-gen-
erating’) procedures, their financial contribution to
departments of medicine is smaller than that of most
other subspecialties. In countries where the health
care budget is mainly calculated on the basis of in-
patient hospital care, the position of clinical endocrin-
ology which has become more and more an out-patient
specialty has weakened considerably. Nonetheless, a
recent survey in The Netherlands showed that about
30% of all patients seen by internists have diseases
which are part of clinical endocrinology.
In the present article we analyze the position of clini-
cal endocrinology, describing ‘the endocrine patient’ of
the past, the present, and especially of the future. In
addition, the necessary infrastructure of an endocrine
division, as well as some aspects of education are
discussed.
The case of diabetes mellitus
Up until 1921, the year that insulin was discovered,
most diabetic patients rapidly died from hyperglycemic
coma despite rigorous dietary regulation (8, 9). The dis-
covery and clinical introduction of insulin enormously
improved this life-threatening condition, and it was
infections, especially tuberculosis, which became the
leading causes of death in patients with diabetes mellitus
in the subsequent 20 years (Fig. 1). The discovery of anti-
biotic and tuberculostatic drugs diminished infection-
related deaths in the subsequent 20 years. During this
period secondary complications in the kidney were
recognized in the now much longer surviving patients
and by 1950 –1960 renal insufficiency became the
major cause of death. Renal dialysis and later kidney
transplantation virtually eliminated renal failure as a
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primary cause of death in diabetic patients in the sub-
sequent years. Thereafter, cardio- and cerebro-vascular
death became the most prominent cause of death at
the turn of the century. Coronary heart surgery, coron-
ary artery angioplasty, and new medical treatments
lowering blood pressure, lipids and glucose levels have
now been implemented in the daily treatment regimens
of all diabetic patients.
The disease diabetes mellitus has been ‘transmuted’
several times during the 20th century both with
regard to its course, as well as its cause (10). Until
1950 it was mainly type 1 diabetic patients suffering
from auto-immune destruction of pancreatic b-cells
that lived longer and longer as a consequence of the
application of a number of major breakthroughs in
endocrine and medical research, the biggest being the
discovery of insulin. The number of patients that it
was necessary to treat in order to prevent death by
insulin was close to one. After 1950 an enormous
switch in life style occurred in Western societies.
A rapidly increasing number of patients presented
themselves with type 2 diabetes mellitus, a disease
which is, in the vast majority of cases, related to obesity.
Diabetes mellitus now affects between 5 (Western
Europe) and 7.8% (USA) of the population, and patients
with type 1 diabetes now account for only 5–10% of all
diabetes cases.
In a prediction model developed for the Dutch popu-
lation it was calculated that diabetes mellitus would not
occur in 68% of female and 54% of male patients if the
complete population would lose body weight to such an
extent that obesity and overweight were eliminated. If
the prevalence of physical inactivity could be elimi-
nated, 22% (both females and males) of type 2 diabetes
cases would be prevented. A combination of eliminat-
ing overweight, obesity and physical inactivity would
prevent 75% (females) and 64% (males) of all cases of
type 2 diabetes (11).
This epidemic of type 2 diabetes patients, together
with new pathophysiological insights into the long-
term effects of elevated glucose levels, elevated blood
pressure and elevated lipid levels on the premature
development of secondary complications and acceler-
ated atherosclerosis has resulted in a massive medicali-
zation of these patients. Many patients take 4–8
different types of medication over the 24-h period.
In a recent meta-analysis of randomized controlled
trials it was summarized that with regard to preventing
cardiovascular mortality in type 2 diabetic patients the
person-years that it is necessary to treat in order to pre-
vent one death was over 400 for intensive glucose-low-
ering treatment, 265 for cholesterol-lowering
medication, and about 125 for blood pressure lowering
medication (including ACE-inhibitors) (12).
Over a period of 80 years diabetes mellitus has
turned from a rare endocrine disease (deficiency of a
hormone) which was treated by clinical endocrinolo-
gists into an epidemic (mostly caused by resistance to
Figure 1 Causes of death of patients with diabetes mellitus in the 20th century. The left part of the figure (up to 1950) has been drawn
on the basis of data in type 1 diabetic patients in the USA. These data were collected by E P Joslin (8, 9). The data in the right part of
the figure (after 1950) represent the causes of death in patients with type 1 and type 2 diabetes mellitus in The Netherlands (supplied
by the Dutch Diabetes Federation).
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a hormone) which is treated by general practitioners,
nephrologists, cardiologists and internists primarily
interested in vascular disease without or with an
often marginal education in endocrinology.
Complete therapeutic breakthroughs
versus ‘half-way technologies’: the
creation of the chronic endocrine patient
Clinical endocrinology is one of the most quantitative
and precise clinical disciplines as well as being one of
the most successful (13). The availability of specific
and sensitive hormone assays, dynamic tests of endo-
crine function, and advanced imaging techniques
allows a highly efficient (early) diagnosis of an increas-
ing number of endocrine diseases. However, a complete
cure of these diseases is, in most instances, only offered
by the (experienced) surgeon (e.g. primary hyperpar-
athyroidism, removal of a ‘cold’ nodule in localized
thyroid cancer, laparoscopic removal of steroid-produ-
cing adrenal adenomas and pheochromocytomas,
transsphenoidal selective adenomectomy of pituitary
microadenomas). In many endocrine diseases, however,
the effects of medical, surgical and/or radiation therapy
are often just too much or too little (e.g. management
of Graves’ disease, therapy of pituitary macroadenomas,
assisted reproduction, treatment of type 1 and 2 dia-
betes, obesity). Many of the treatments in endocrin-
ology are imperfect and are not directly targeted at
the underlying pathophysiologies. These ‘half-way
technologies’ (14) create ‘the chronic endocrine
patient’ and many or these patients will remain
under endocrine care for prolonged periods of time.
Pharmaceutical techniques have enabled endocrine
replacement with pure, synthesized hormones and
even designer molecules, like the new insulins.
However, even the seemingly straightforward replace-
ment therapy with hormones, like thyroxine (T4),
hydrocortisone, sex steroids, growth hormone and
vitamin D is not perfect. Although related mortality
has virtually been eliminated, the quality of life of
many patients on (combined) replacement therapy
with these hormones often remains not optimal.
Many patients complain of tiredness and other vague
problems, which suggest intrinsic imperfections of the
hormone replacement strategies used to mimic
normal hormone secretion (15 –24). Most patients
are offered standard doses of hormone replacement,
while the measurement of plasma concentrations of
thyrotropin (TSH), adrenocorticotropin, luteinizing
hormone, follicle-stimulating hormone, free T4, corti-
sol, estradiol, testosterone, insulin-like growth factor-I
(IGF-I) and calcium do not necessarily reflect the
tissue effects in non-endocrine target tissues.
At present, the interest in research in the field of hor-
mone (replacement) therapy seems, at least in part, to
be commercially driven (25). Financial support by
drug companies not only by stimulating clinical
research, but also by sponsoring and influencing meet-
ings and symposia contributes to an increasing number
of publications in the field of growth hormone treat-
ment, whereas the number of publications on hydrocor-
tisone and thyroxine treatment demonstrate a
downwards trend, which by extrapolation might fully
disappear around the year 2009 (Fig. 2). Interestingly,
the daily costs of hormone replacement therapy in The
Netherlands with hydrocortisone, thyroxine, vitamin D,
testosterone, estradiol and growth hormone (GH)
respectively turns out to be inversely related to the
number of yearly publications concerning their use in
treatment (P , 0.01).
What can be done in the coming years to improve this
rather disappointing scene of a too aggressive treatment
of hyperthyroidism (resulting frequently in hypothyroid-
ism), of assisted reproduction (resulting frequently in
multiple pregnancies) and of pituitary macroadenomas
(resulting frequently in hypopituitarism)? New insights
in the prevention and treatment of (auto-)immune
diseases, individualized gradual ovulation induction, as
well as the development of more potent and subtype-
specific dopamine and somatostatin receptor analogs
should eventually diminish the creation of so many
‘chronic endocrine patients’. Hormone replacement
therapy will be improved by determining the actual
dose needed in individual patients by characterizing the
set-points of their pituitary–thyroid, pituitary–adrenal,
as well as GH–IGF-I axes, by studying frequently occur-
ring polymorphisms in the thyroid hormone receptor
and deiodinases, the glucocorticoid receptor and the
IGF-I genes (26 –29).
Molecular endocrinology
The characterization of a number of single-gene
endocrine disorders has contributed to our understand-
ing of the pathophysiology of these disorders (13). The
availability of genetic tools has expanded our knowledge
about the pathogenesis of such diverse conditions as
precocious puberty, McCune Albright syndrome,
Carney’s syndrome, about 30% of acromegalic
pituitary tumors, toxic thyroid adenomas, and (bilat-
eral) hyperplastic and/or adenomatous adrenal
tumors causing Cushing’s syndrome. However, the
practical use of DNA diagnostics in day-to-day clinical
endocrinology remains mainly limited to those few
families with multiple endocrine neoplasia (type 1 and
2) and Von Hippel-Lindau’s disease. In these hereditary
tumor syndromes DNA examination of (newborn)
family members is helpful in the early diagnosis, as
well as in carrying out preventive surgical intervention
(e.g. medullary thyroid cancer). However, in neonatal
population screening for 21-hydroxylase deficiency,
congenital hypothyroidism and phenylketonuria, the
measurements of serum 17-hydroxyprogesterone, T4
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and/or TSH and phenylalanine concentrations remain
first choice, because the genotypic abnormalities do
not adequately predict the phenotypic changes. Matur-
ity-onset diabetes of the young (MODY) might be an
example of a genetic disease in which the knowledge
of specific gene mutations might be of importance to
predict the course of disease progression, as well as
the choice of optimal therapy (30, 31).
For the more frequently occurring hereditary
endocrine and metabolic diseases which occur during
adulthood, more and more doubts about the predictive
value of determining the genetic abnormalities for the
phenotypic expression are being reported. The actual
chance of developing clinically significant conse-
quences of iron deposition, even in homozygotically
affected individuals with mutations in the HFE gene
might be very low (32). The measurement of ferritin
or iron saturation percentages of transferrin seem of
comparable predictive clinical value for screening pur-
poses. In the case of familial hypercholesterolemia
also a discrepancy has become increasingly clear
between the genotype and phenotype (33). Other mod-
ifying genes affecting high density lipoprotein (HDL)-
cholesterol, triglyceride and/or homocystein levels,
and especially life-style play a deciding role as to
whether a certain mutation in the low density lipopro-
tein (LDL)-receptor gene results in clinically significant
premature atherosclerosis (34 –36).
Hereditary hemochromatosis and familial hypercho-
lesterolemia are caused by germ-line mutations which
inherit in a Mendelian fashion. These mutations have a
high penetrance on the biochemical variables (iron sat-
uration, LDL-cholesterol), but with unpredictable geno-
type –phenotype relationships. In most common
endocrine diseases the hereditary component is even
less strong, making them from a genetic standpoint
‘complex’ (37 –39). Many ‘genocentric’ investigators
predict that genetic markers for disease susceptibility
will, in the immediate future, have a large impact
in endocrinology and medicine (40). However, one
should not forget that, in contrast to the rare high pene-
trance single gene disorders, gene polymorphisms which
in large population studies have been associated with
certain risks form an insufficient basis for (preventive)
treatment. In most cases these ‘predictive’ polymorphic
sites in susceptibility genes may not result in symptoms
(hypertension, obesity, diabetes, fractures) for many
years to come. In addition, their predictive power is at
present in all cases insufficient to allow the start of pre-
mature medicalization in genetically defined individuals.
In the near future, therefore, clinical endocrinologists
will continue to use the well-known, more powerful pre-
dictive intermediates, like organ-specific autoantibodies,
blood pressure, serum cholesterol concentrations,
intima thickness of the carotid artery, smoking and diet-
ary habits, body weight, and activity patterns in predic-
tive models of these complex diseases. It might take
years before genetic variants can be included in these
predictive models, bringing secondary prevention on
the basis of genetic analysis into the center of clinical
endocrinology. For the time being, genetic analysis of
blood or tissue in endocrinology remains reserved for a
small number of rare diseases.
In the meantime, molecular endocrinology will con-
tinue to offer us new insights into the molecular basis
of tissue regulation of hormone sensitivity, in the phys-
iological functions of the many remaining orphan
nuclear receptors, and in the pathophysiological role
of the new hormones that are discovered every year.
High-throughput genomics and proteomics with com-
puter modeling will allow development of new drugs
specifically interfering with hormone receptors.
Figure 2 The number of publications in PubMed with hydrocortisone, thyroxine or growth hormone in the title (restricted to 5-year
intervals).
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The changing endocrine patient: the
impact of life-style drugs and the
prevention of aging
In a recent debate in the British Medical Journal on
‘non-diseases’ it was concluded that the concept of
what is and what is not a disease has become slippery
(41). It was observed that pharmaceutical companies
have a clear interest in medicalizing life’s problems
and/or perceived shortcomings, for which they try to
create designated medication (42).
The field of endocrinology seems especially prone to a
tendency where new treatments are actively pursued
by, but not offered to, otherwise healthy individuals.
More and more people ask for medical intervention in
life’s normal processes, seeking to increase body
height of their children (in normal short stature), to
regulate appetite and body composition (e.g. over-
weight, obesity, muscle mass and strength), sexuality
(libido and potency), reproduction (assisted reproduc-
tion later in life, gender preference for children), and
to prevent baldness, wrinkles, as well as to delay the
aging process. Increasing pressures from a growing
population of affluent people, which have great expec-
tations (partially based on browsing the internet) (43)
are about to change the appearance, as well as the
composition of the ‘patient’ population of the endocrine
clinic. Much will now depend on the attitude, the inter-
est, and the reaction of the individual endocrinologist,
as well as of their national endocrine societies.
The medicalization of the reduction in bone mass
which is a physiological part of the aging process is a
tentative example of a risk factor which seems to have
become conceptualized as a disease by many individuals.
Is it advisable to measure bone mineral density in all
healthy women after menopause? When should long-
term preventive drug treatment be offered? A 4-year
treatment of menopausal women with slightly lowered
bone mineral density without fractures with a bisphos-
phonate lowered the incidence of vertebral fractures
from 3.8% to 2.1% (44). One can look at these results
in two ways: as a very slight decrease of the absolute
risk by 1.7%, or as a very promising 44% relative risk
reduction.
In ‘the endocrinology of aging’ the concepts of meno-
pause, andropause, adrenopause, and somatopause
have been investigated mainly in cross-sectional and
occasionally in longitudinal population studies (45).
In most instances, in randomized clinical trials the
healthy elderly have been included for treatment with
estrogens, testosterone, dihydroepiandrosterone or GH.
These trials often lack powerful endpoints related to
activities of daily life, independence or quality of life.
They are often of short duration and they very often
suffer from selection bias (45). In the case of estrogen
replacement therapy this has resulted for many years
in what now turns out to be false optimism (46). It is
an absolute requirement that the general principles
of evidence-based medicine are fully implemented by
providers of these medical interventions in the aging
process. In several countries a tendency is noted in
which a new type of clinical endocrinology is created,
which promises ‘eternal youth and beauty’, but it
remains uncertain at what price (financially, as well
as with regard to unknown (long-term) adverse effects).
The medicalization of old age is slowly entering the
endocrine clinic of many of our mainly non-university
based colleagues, and life-style medication for the afflu-
ent adult is about to enter the mainstream of endocrin-
ology. The pressure from society is high, as are the
financial benefits to the medical profession. It will be
an enormous challenge to the endocrine community
to adequately respond to this tendency to greater medi-
cal consumerism. Moreover, we should challenge the
concept of insufficient endocrine function in aging.
There are a large number of animal models which
show that decreased hormone secretion and/or sensi-
tivity (e.g. of GH) increase, rather than decrease
longevity.
Infrastructure and education
Completely integrated endocrine laboratories in which
highly specialized hormone assays, DNA diagnostics,
nuclear medical diagnostics and therapeutics are inte-
grated with the care offered by a group of endocrinolo-
gists remain necessary in order to provide the best care
(47). However, such integrated care is in decline in
Western Europe, even in the academic centers (1–5).
Clinical endocrinologists need a wide range of train-
ing in general internal medicine, but also a deep knowl-
edge in basic science: apart from (molecular) cell
biology, the understanding of hormonal regulation,
feed-back loops and homeostatic mechanisms which
involve the whole body and not just single cells, are
especially essential. Also, it should be realized that
research in the field of endocrinology is widely spread
over many different disciplines including physiology,
pharmacology, and cell biology on the one hand, but
also gynecology, oncology, neurosciences, pediatrics,
urology and other disciplines. Therefore, the scientific
impact of endocrine research is often presented in a
diluted manner diminishing its perceived significance.
A major challenge is to provide strong evidence that
the quality of the care by clinical endocrinologists in
the diagnosis and treatment of diseases of the thyroid,
bone, pituitary, adrenals, but also of obesity, diabetes
and atherosclerosis is clearly better as well as more
cost-effective than that provided by non-endocrinologist
physicians. In a recent study comparing the quality of
care of diabetic patients provided by endocrinologists
and internists working in primary care centers in the
USA, no overall significant differences in care were
found after the application of complex statistical methods
related to case-mix and physician-level clustering.
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However, the data provide clear evidence that better care
was offered by endocrinologists if basic process and out-
come measures like HbA1C, lipid levels, urinary protein
excretion, blood pressure, eye and foot examination
were considered (48). Also, the satisfaction with the
personal care offered by endocrinologists was rated
higher by the patients. In an editorial, the inherent
methodological difficulties of this type of study to
measure quality of care were discussed (49). In
our opinion it is an absolute priority for clinical
endocrinology to optimalize and repeat these types
of studies, and to expand them to other endocrine
disorders as well.
Another aspect of modern health care regulations
which is about to take place in many Western Euro-
pean countries is the evaluation of endocrine clinical
practice with regard to its costs and effectiveness.
New evaluation techniques using health care technol-
ogy assessment methods and specific questionnaires
concerning the quality of life of our patients are
currently developed and will have great impact on
practical patient care in the coming years. Again, it
is a great priority for Western European endocrine
societies to take the lead in these developments,
rather than to wait for external reviewers to develop
these techniques.
Conclusions
Clinical endocrinology is very much alive and will
remain so for many years to come. The ‘chronic endo-
crine patient’ will be replaced by more and more
‘cured’ patients, as knowledge about the pathophysiol-
ogy of auto-immune diseases, reproduction and benign
endocrine tumors expands. Also, hormone replace-
ment therapy will be administered more precisely on
the basis of genetic knowledge of the set-points of
the endocrine axes in the individual patients. The evol-
ution of endocrine concepts will enable a better per-
spective of the underlying pathophysiology and will
result in better treatment of many unresolved endo-
crine diseases. As knowledge about the predictive
value of genetic variations in the genes involved in
the most common complex diseases, which are often
‘endocrine’ in nature, become better known, the role
of the clinical endocrinologist in early risk identifi-
cation and early primary or secondary prevention
will expand. Finally, the application of all principles
of evidence-based medicine will, without doubt,
result in a certain degree of ‘hormonal’ medicalization,
especially of the aging process. However, there will be
increasing pressure from the public on clinical endo-
crinologists to help solve an increasing number of
‘non-diseases’ e.g. variations in life’s normal processes
(sexuality, body height, body composition, muscle
strength, reproduction). It is an enormous challenge
to endocrinology, to the clinical endocrinologist, and
to their respective national endocrine societies, to get
this right.
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